A Randomised Phase III Study of the duration of the Anti-PD1 - therapy in metastatic melanoma (STOP-GAP)

PD-1抑制剂可以激活免疫系统，这样它就可以对抗体内的癌细胞，并对黑色素瘤有效。这项研究调查了中断PD-1抑制剂剂量是否不会比连续治疗24个月的黑色素瘤结果更差，这可能会减少与治疗相关的毒性，改善患者的生活质量，并降低医疗系统和个人的治疗成本。这一结果可能会为其他常见癌症的治疗提供参考。

PD-1 inhibitors turn on the immune system,so that it can fight the cancer cells in the body and are effective in Melanoma. This study investigates whether interrupted PD-1 inhibitor dosing has no worse Melanoma outcome than continuous treatment for 24 months, which may lead to a reduction in treatment-related toxicities, improvements in patients' quality of life and decrease the cost of treatment to the health system as well as individual. Results may inform treatments for other common cancers.